Chemotherapy - Pharmacy Technician Pulse

STAT+: Drug may make chemotherapies less effective in cancer patients with obesity — but many doctors are in the dark

STAT

OCTOBER 28, 2024

This means chemotherapies may be less effective when interacting with the medicine, but some clinicians, and their patients, are unaware of that possibility. A drug used to combat fungal infections in cancer patients comes with a big caveat — research shows the medicine can last twice as long as in people with obesity.

Chemotherapy

Chemotherapy Labelling

ASCO 2025: Informing Treatment Decisions Using a 14-Gene Assay in Early-Stage NSCLC

Pharmacy Times

JUNE 2, 2025

A study reveals a 14-gene assay guides chemotherapy decisions effectively in patients with early-stage non-small cell lung cancer (NSCLC).

Chemotherapy

STAT+: Jazz Pharmaceuticals to acquire Chimerix and its experimental brain cancer drug

STAT

MARCH 5, 2025

It responds poorly to chemotherapy and is usually driven by a mutation that can’t be drugged with traditional approaches. The tumor, known as diffuse midline glioma, or DMG (and sometimes as DIPG depending on where it’s found), has flummoxed researchers for decades. Median survival is generally cited as less than a year.

Chemotherapy

Q&A: How IQVIA Keeps Pharmacists Engaged with US Prescription Drug Use

Drug Topics

JULY 14, 2025

Often those very high-end medicines are for very few people.

Immunization

Immunization Compounding Specialty Pharmacies Independent Pharmacies

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

This new guidance will clearly impact the clinical research field, but how?

FDA

Assessing Prescriber Justification for Use of Outpatient Chemotherapy in the Acute Care Setting

Pharmacy Times

JUNE 17, 2025

This single-center, descriptive, retrospective chart review identified barriers to outpatient chemotherapy use, revealing avoidable inpatient stays and highlighting targets for stewardship interventions.

Chemotherapy

Is prescribing anticancer drugs by body surface area still relevant?

Hospital Pharmacy Europe

JANUARY 23, 2025

The approach was adopted widely, particularly for cytotoxic chemotherapy agents, with the aim of standardising drug exposure and minimising toxicity. 5,6 Freireich et als work further validated this approach, showing that BSA correlated with drug efficacy and toxicity across several chemotherapy agents. 6 Gurney H.

Chemotherapy

Chemotherapy Hospitals Dosage Pharmaceutical Companies

With ADCs on the rise, drugmakers embrace a new oncology pillar

PharmaVoice

JUNE 6, 2025

At ASCO, one of the most talked-about studies was a late-stage trial in which the treatment outperformed chemotherapy as a first-line drug. As we move earlier, almost all of our trials will be in combination with different [immuno-oncology] drugs and … even chemotherapy drugs,” Keller said. “As

Chemotherapy

Chemotherapy FDA

The MEK effect on cancer — a slow and steady approach to drug resistance

PharmaVoice

JULY 8, 2025

This slow and steady concept gained more validation in June when the company announced early but promising data from a phase 2 trial of its MEK inhibitor atebimetinib combined with chemotherapy, which showed a six-month 94% overall survival in pancreatic cancer.

Immunization

Immunization Chemotherapy Insurance Packaging

Insights From ASCO 2025 Guide Pharmacy Practice in Solid Tumors and Hematologic Cancers

Pharmacy Times

JULY 16, 2025

The findings of the DeLLphi-304 study demonstrated improved OS of tarlatamab compared with single-agent chemotherapy (median OS [mOS], 13.6 The updated definition for HRMM is increasingly important as there is an increased focus on how to improve outcomes for patients with HRMM, functional HRMM, and true extramedullary disease.

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents Compounding Pharmacies Immunization Chemotherapy

New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma

Pharmacy Times

JUNE 27, 2025

Because of its aggressive nature, MCL is typically treated with combination chemotherapy at diagnosis. For this application, the FDA collaborated with the Australian Therapeutic Goods Administration, Health Canada, and Switzerland’s Swissmedic.

FDA

FDA Compounding Pharmacies Immunization Chemotherapy

Pharmacies Need Strategies to Improve Health Care Access

Pharmacy Times

JUNE 18, 2025

Martino, PharmD, BCOP, APh Kaitlyn Wells, PharmD Sam Martinez, PharmD, BCOP, BCPS Craig A. Martino, PharmD, BCOP, APh Kaitlyn Wells, PharmD Sam Martinez, PharmD, BCOP, BCPS Craig A.

Immunization

Immunization Compounding Pharmacies Hospitals Chemotherapy

NICE recommends new combination breast cancer drug

European Pharmaceutical Review

APRIL 11, 2025

It could potentially delay patients requiring chemotherapy and subsequently experiencing the associated side-effects, Helen Knight, Director of Medicines Evaluation at NICE explained. months with chemotherapy only. As a twice-daily tablet, capivasertib can be administered when patients have limited treatment options.

Chemotherapy

The Value of a Medically Integrated Pharmacy to Maximize Cost Avoidance and Reduce Waste of Oral Oncolytic Medications

Pharmacy Times

JUNE 17, 2025

Download Issue PDF Download RIS Articles in this issue The Value of a Medically Integrated Pharmacy to Maximize Cost Avoidance and Reduce Waste of Oral Oncolytic Medications Prevalence of Dosage Modifications and Impact on Response Milestone Among Patients With CML Treated With Imatinib Using RWD Assessing Prescriber Justification for Use of Outpatient (..)

Mail-Order Pharmacies

Mail-Order Pharmacies Compounding Pharmacies Medical Records Dosage

Immunotherapy Takes the Lead in Advanced Cutaneous Malignancies

Pharmacy Times

JUNE 20, 2025

Blood cancer patients are usually at higher risk due to prior chemotherapy, and maybe we don’t need the same kind of prophylactic medications for solid tumor patients. I think we’re getting to the point now where hematology and oncology both need services that can manage these types of side effects. The infection risks are a little different.

Compounding Pharmacies

Compounding Pharmacies Immunization Mayo Clinic Hospitals

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

Pharmacy Times

JUNE 23, 2025

Download Issue PDF Download RIS Articles in this issue Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement Unicorns Don’t Exist: Rethinking the Generalist Model in Oncology Pharmacy CAR T and Beyond: The Expanding Pipeline and Promise of Cell Therapies Operationalizing Precision Oncology: The Expanding Role of the Clinical Precision Medicine (..)

FDA

FDA Compounding Pharmacies Dosage Hospitals

Impact of Patient Access to Care on Rates of Febrile Neutropenia Post Inpatient Administration of a Colony-Stimulating Factor

Pharmacy Times

JUNE 16, 2025

Transportation barriers, as a health-related social need, significantly impact FN rates in chemotherapy patients. Febrile neutropenia (FN) remains a serious and common complication of chemotherapy. This study explored the understudied area of health-related social needs (HRSNs) in the context of patients receiving chemotherapy.

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents Chemotherapy Compounding Pharmacies Immunization

Steroid Use During ICI Treatment Lessens Effectiveness in Patients With NSCLC

Pharmacy Times

JULY 9, 2025

Although improved clinical outcomes with the addition of chemotherapy to ICI have been recorded for some patients, there is ongoing research to understand how prognostic factors (eg, smoking history, tumor histology, performance status) can provide some predictive values for patient response to ICI therapy.

Immunization

Immunization Compounding Pharmacies FDA Chemotherapy

Unicorns Don’t Exist: Rethinking the Generalist Model in Oncology Pharmacy

Pharmacy Times

JUNE 20, 2025

Download Issue PDF Download RIS Articles in this issue Unicorns Don’t Exist: Rethinking the Generalist Model in Oncology Pharmacy CAR T and Beyond: The Expanding Pipeline and Promise of Cell Therapies Operationalizing Precision Oncology: The Expanding Role of the Clinical Precision Medicine Oncology Pharmacist Sequencing of Liposomal Daunorubicin/Cytarabine (..)

Compounding

Compounding Compounding Pharmacies Patient Care Immunization

Prevalence of Dosage Modifications and Impact on Response Milestone Among Patients With CML Treated With Imatinib Using RWD

Pharmacy Times

JUNE 17, 2025

Conclusions We demonstrated the feasibility of leveraging a complex EHR data source from an integrated health system to study the impact of dose modifications on clinical outcomes for self-administered chemotherapy. Nearly half of the patients with CML on imatinib experienced dosage modifications in this study.

Dosage

Dosage Compounding Pharmacies Immunization Chemotherapy

Pharmacists at the Frontlines of Innovation in Lung Cancer Care

Pharmacy Times

JUNE 25, 2025

Yes, we currently have antibody-drug conjugates that are conjugated to a cytotoxic chemotherapy. So are there oncogenic proteins that we can actually target that we couldn’t traditionally target with just a small molecule inhibitor? We look at ADCs. Unfortunately, these drugs are quite toxic.

Compounding Pharmacies

Compounding Pharmacies Immunization Hospitals Compounding

CAR T and Beyond: The Expanding Pipeline and Promise of Cell Therapies

Pharmacy Times

JUNE 19, 2025

Trends Pharmacol Sci. 2024;45(5):406-418. doi:10.1016/j.tips.2024.03.004

Compounding

Compounding Compounding Pharmacies FDA Immunization

Investigating the Pharmacist’s Role in Psychedelic-Assisted Psychotherapy for Patients With Cancer

Pharmacy Times

JUNE 27, 2025

After learning of his diagnosis, our relationship shifted from small talk at school events to detailed discussions in an infusion center setting about chemotherapy, immunotherapy, clinical trials, alternative medicines, and anticipated adverse effects.

Compounding Pharmacies

Compounding Pharmacies Immunization Chemotherapy Hospitals

Big pharma braces for revenue headwinds as patent expiries loom

Pharmaceutical Technology

JULY 4, 2025

Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Nominate Now Share Copy Link Share on X Share on Linkedin Share on Facebook Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Find out more Sign up for our daily news round-up!

Chemotherapy

Chemotherapy Packaging Communication Hospitals

Six Biosimilars Part of EMA’s Authorization Recommendations in June

PharmTech

JUNE 23, 2025

Zemcelpro is used to treat patients that require allogeneic hematopoietic stem cell transplantation following chemotherapy or radiotherapy when no other type of suitable donor cells is available. Two generic drugs were also approved.

Dosage

Dosage Chemotherapy Packaging

EU’s Pharma Package falls short of Europe’s goal of global competitiveness

Pharmaceutical Technology

JULY 1, 2025

Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Sign up Share Copy Link Share on X Share on Linkedin Share on Facebook Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Sign up for our daily news round-up!

Packaging

Packaging Chemotherapy Communication Hospitals

Anlotinib Following Benmelstobart Plus Chemotherapy Improves Progression-Free Survival in S-NSCLC

Pharmacy Times

JUNE 25, 2025

Benmelstobart (TQB2450; Chia Tai Tianqing Pharmaceutical Group Co, Ltd) in combination with chemotherapy followed by sequential combination with anlotinib (Catequentinib; Advenchen Laboratories) led to significant improvements in progression-free survival (PFS), with a manageable safety profile. months versus 7.79 months with tislelizumab.

Chemotherapy

Chemotherapy Compounding Pharmacies Immunization Hospitals

Sequencing of Liposomal Daunorubicin/Cytarabine Versus Hypomethylating Agents Plus Venetoclax for Secondary Acute Myeloid Leukemia

Pharmacy Times

JUNE 18, 2025

Download Issue PDF Download RIS Articles in this issue Sequencing of Liposomal Daunorubicin/Cytarabine Versus Hypomethylating Agents Plus Venetoclax for Secondary Acute Myeloid Leukemia Clinical Manifestations of Acute, Chronic Graft-vs-Host Disease With PTCy in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation The Value of a Medically (..)

Compounding Pharmacies

Compounding Pharmacies Dosage Immunization Hospitals

TRE-5151 Receives FDA Fast Track Designation in Combination With Radiation Therapy for Prostate Cancer

Pharmacy Times

JULY 14, 2025

TRE-515 Combined With a Radiopharmaceutical As a precision cancer treatment designed for adults with PSMA-positive mCRPC, lutetium Lu 177 vipivotide tetraxetan is used after individuals have undergone other treatments like androgen receptor pathway inhibition and taxane-based chemotherapy.

FDA

FDA Compounding Pharmacies Compounding Immunization

From Trial to Practice in the Evolving Landscape of Hematologic Malignancies

Pharmacy Times

JUNE 18, 2025

Mok : Right now, we have a lot of chemotherapy being used, but there are many more novel treatments being studied, especially in earlier lines of treatment. Bispecifics are moving up in the lymphoma space, and these newer therapies may have some synergistic effects with chemotherapy. REFERENCES 1. Updated August 18, 2021.

Chemotherapy

Chemotherapy Compounding Pharmacies Immunization Hospitals

Reinventing Transplant Care: From Inpatient Tradition to Outpatient Innovation

Pharmacy Times

JULY 3, 2025

I think it’ll be chemotherapy—maybe their cells being given outpatient—and then, as we hit their hardest time or their highest risk for either febrile neutropenia or mucositis or even some of the toxicities from the chemotherapy, we have them inpatient until we feel comfortable, and then transition it so that it could be all outpatient.

Specialty Pharmacies

Specialty Pharmacies Compounding Pharmacies Hospitals Immunization

Can you take antibiotics for yeast infections?

The Checkup by Singlecare

APRIL 29, 2025

Other risk factors include: Pregnancy Birth control pills Hormonal changes during the menstrual cycle Unmanaged Type 2 diabetes A weakened immune system from HIV/AIDs, certain medications, or chemotherapy and radiation therapy Other triggers include wearing tight or non-breathable clothing, wearing damp workout clothes or swimsuits too long, and using (..)

Immunization

Immunization Chemotherapy

FDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiency

Pharmaceutical Technology

JULY 1, 2025

In June 2025, the European Commission authorised Takeda’s Adcetris (brentuximab vedotin), an antibody-drug conjugate, combined with chemotherapy for treating adults who are newly diagnosed with Stage IIb Hodgkin’s lymphoma with risk factors or at Stage III/IV. Sign up for our daily news round-up!

FDA

FDA Packaging Communication Hospitals

Navigating EGFR Mutations and ALK Fusions in Early-Stage Non-Small Cell Lung Cancer

Pharmacy Times

JUNE 19, 2025

1 Biomarker testing is relatively new in the treatment landscape for NSCLC but has proven incredibly important for personalizing patient care, transforming from a generic chemotherapy approach to a highly personalized, genomically driven treatment strategy. For advanced disease, chemotherapy was the standard.

Chemotherapy

Chemotherapy Compounding Pharmacies Hospitals Immunization

Major immunotherapy trial sees survival benefit in solid tumours

European Pharmaceutical Review

NOVEMBER 11, 2024

Notably, participants given the chemotherapy and EBV-specific cytotoxic T cell (EBV-CTL) therapy achieved better progression free survival and overall survival compared to those who received chemotherapy only. A prior Phase II trial showed benefit of giving T cell therapy following first line chemotherapy.

Chemotherapy

Biocon’s Denosumab biosimilars gain EU marketing authorisation

Pharmaceutical Technology

JULY 4, 2025

Go deeper with GlobalData Reports LOA and PTSR Model - Denosumab Biosimilar in Bone Metastasis Reports LOA and PTSR Model - Denosumab Biosimilar in Chemotherapy Effects Data Insights The gold standard of business intelligence. Find out more Sign up for our daily news round-up! Give your business an edge with our leading industry insights.

Chemotherapy

Chemotherapy Packaging Communication Hospitals

Real-World Data Suggests Cannabis Use is Associated With Major Adverse Cardiovascular Events

Pharmacy Times

JUNE 25, 2025

[link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. Subscribe Now!

Compounding Pharmacies

Compounding Pharmacies Immunization Chemotherapy Hospitals

How much is fluorouracil without insurance?

The Checkup by Singlecare

JULY 2, 2025

Fluorouracil, sometimes called 5-FU, is a prescription chemotherapy drug used in the treatment of many types of cancers. It is available both as an injection and a topical product. Without insurance, one 40 gm tube of fluorouracil 5% topical cream costs about $363.

Insurance

Insurance Insurance Coverage Chemotherapy Documentation

Clinical Manifestations of Acute, Chronic Graft-vs-Host Disease With PTCy in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation

Pharmacy Times

JUNE 18, 2025

Download Issue PDF Download RIS Articles in this issue Sequencing of Liposomal Daunorubicin/Cytarabine Versus Hypomethylating Agents Plus Venetoclax for Secondary Acute Myeloid Leukemia Clinical Manifestations of Acute, Chronic Graft-vs-Host Disease With PTCy in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation The Value of a Medically (..)

Compounding Pharmacies

Compounding Pharmacies Dosage Immunization Hospitals

J&J eyes prostate cancer label expansion for Akeega

Pharmaceutical Technology

JULY 7, 2025

Find out more J&J’s drug is an option for patients where medical or surgical treatment to lower testosterone levels has not worked, and in those who have BRCA 1/2 mutations – a subset of homologous recombination repair (HRR) mutations – in whom chemotherapy is not indicated.

Labelling

Labelling Packaging Communication Hospitals

AstraZeneca’s Imfinzi approved in Europe for muscle-invasive bladder cancer

Pharmaceutical Technology

JULY 4, 2025

Imfinzi is now approved to treat adult patients with resectable muscle-invasive bladder cancer (MIBC) in combination with chemotherapy drugs gemcitabine and cisplatin as neoadjuvant treatment, and as a monotherapy after bladder removal surgery. Imfinzi is a major revenue driver for AstraZeneca, generating around $4.7bn in sales in 2024.

Chemotherapy

Chemotherapy Packaging Labelling Communication

Novartis and Ratio to progress next-gen radiotherapeutic

European Pharmaceutical Review

NOVEMBER 19, 2024

.” In a Q&A with EPR last year, Hoppin and Ratio’s Director, President and Chief Scientific Officer, Dr John Babich, described that “there is great hope of this class of drug specifically to work in conjunction with immunotherapeutics, given the lack of toxicity of radiopharmaceuticals in general compared to most chemotherapies.”

Chemotherapy

Chemotherapy FDA

Study: Prevalence and Clinical Implications of MASLD in Type 2 Diabetes

Pharmacy Times

JUNE 17, 2025

Martino, PharmD, BCOP, APh Kaitlyn Wells, PharmD Sam Martinez, PharmD, BCOP, BCPS Craig A. Stevens, PharmD, BCPS June 3rd 2025 S2. Martino, PharmD, BCOP, APh Kaitlyn Wells, PharmD Sam Martinez, PharmD, BCOP, BCPS Craig A. Stevens, PharmD, BCPS June 3rd 2025 S2.

Compounding Pharmacies

Compounding Pharmacies Hospitals Immunization Chemotherapy

Tarlatamab Significantly Improves Survival in Patients With Small Cell Lung Cancer Post-Progression

Pharmacy Times

JUNE 6, 2025

Granted accelerated approval by the FDA in 2024, tarlatamab continues to demonstrate efficacy and safety in patients with small cell lung cancer, with results showing improved overall survival and progression-free survival in patients who had progressed or previously received chemotherapy.

Chemotherapy

Chemotherapy FDA

STAT+: Drug may make chemotherapies less effective in cancer patients with obesity — but many doctors are in the dark

ASCO 2025: Informing Treatment Decisions Using a 14-Gene Assay in Early-Stage NSCLC

Trending Sources

STAT+: Jazz Pharmaceuticals to acquire Chimerix and its experimental brain cancer drug

Q&A: How IQVIA Keeps Pharmacists Engaged with US Prescription Drug Use

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Assessing Prescriber Justification for Use of Outpatient Chemotherapy in the Acute Care Setting

Is prescribing anticancer drugs by body surface area still relevant?

With ADCs on the rise, drugmakers embrace a new oncology pillar

The MEK effect on cancer — a slow and steady approach to drug resistance

Insights From ASCO 2025 Guide Pharmacy Practice in Solid Tumors and Hematologic Cancers

New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma

Pharmacies Need Strategies to Improve Health Care Access

NICE recommends new combination breast cancer drug

The Value of a Medically Integrated Pharmacy to Maximize Cost Avoidance and Reduce Waste of Oral Oncolytic Medications

Immunotherapy Takes the Lead in Advanced Cutaneous Malignancies

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

Impact of Patient Access to Care on Rates of Febrile Neutropenia Post Inpatient Administration of a Colony-Stimulating Factor

Steroid Use During ICI Treatment Lessens Effectiveness in Patients With NSCLC

Unicorns Don’t Exist: Rethinking the Generalist Model in Oncology Pharmacy

Prevalence of Dosage Modifications and Impact on Response Milestone Among Patients With CML Treated With Imatinib Using RWD

Pharmacists at the Frontlines of Innovation in Lung Cancer Care

CAR T and Beyond: The Expanding Pipeline and Promise of Cell Therapies

Investigating the Pharmacist’s Role in Psychedelic-Assisted Psychotherapy for Patients With Cancer

Big pharma braces for revenue headwinds as patent expiries loom

Six Biosimilars Part of EMA’s Authorization Recommendations in June

EU’s Pharma Package falls short of Europe’s goal of global competitiveness

Anlotinib Following Benmelstobart Plus Chemotherapy Improves Progression-Free Survival in S-NSCLC

Sequencing of Liposomal Daunorubicin/Cytarabine Versus Hypomethylating Agents Plus Venetoclax for Secondary Acute Myeloid Leukemia

TRE-5151 Receives FDA Fast Track Designation in Combination With Radiation Therapy for Prostate Cancer

From Trial to Practice in the Evolving Landscape of Hematologic Malignancies

Reinventing Transplant Care: From Inpatient Tradition to Outpatient Innovation

Can you take antibiotics for yeast infections?

FDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiency

Navigating EGFR Mutations and ALK Fusions in Early-Stage Non-Small Cell Lung Cancer

Major immunotherapy trial sees survival benefit in solid tumours

Biocon’s Denosumab biosimilars gain EU marketing authorisation

Real-World Data Suggests Cannabis Use is Associated With Major Adverse Cardiovascular Events

How much is fluorouracil without insurance?

Clinical Manifestations of Acute, Chronic Graft-vs-Host Disease With PTCy in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation

J&J eyes prostate cancer label expansion for Akeega

AstraZeneca’s Imfinzi approved in Europe for muscle-invasive bladder cancer

Novartis and Ratio to progress next-gen radiotherapeutic

Study: Prevalence and Clinical Implications of MASLD in Type 2 Diabetes

Tarlatamab Significantly Improves Survival in Patients With Small Cell Lung Cancer Post-Progression

Stay Connected